On Nov 02, major Wall Street analysts update their ratings for $Merck & Co (MRK.US)$, with price targets ranging from $120 to $125.
Morgan Stanley analyst Terence Flynn maintains with a hold rating, and maintains the target price at $123.
BofA Securities analyst Charlie CY Yang maintains with a buy rating, and maintains the target price at $120.
UBS analyst Colin Bristow maintains with a buy rating, and adjusts the target price from $142 to $125.
Leerink Partners analyst Joseph Schwartz maintains with a buy rating.
Furthermore, according to the comprehensive report, the opinions of $Merck & Co (MRK.US)$'s main analysts recently are as follows:
Ongoing uncertainty surrounding Gardasil and the market in China as we approach 2024 has been highlighted following the company's third quarter report. The analyst has revised estimates subsequent to the third quarter earnings surpassing expectations and the company largely maintaining its outlook.
Merck's third-quarter results slightly surpassed expectations in terms of revenue and earnings. Despite this, the company's stock faced a bit of pressure following the adjustment of their revenue forecast and a reduction in EPS guidance, now anticipated to be between $7.72 and $7.77, primarily due to a charge associated with previous acquisitions. Looking ahead, while revenue projections for 2024 remain largely the same with a slight increase in EPS expectations, estimates for 2025 have been scaled back on account of anticipated lower Gardasil sales and heightened operational expenditures.
Merck's adjustment of expectations for Gardasil is seen as a positive development, although the introduction of new investments may still require a shift in narrative. The potential of Winrevair to catalyze this change remains uncertain.
Here are the latest investment ratings and price targets for $Merck & Co (MRK.US)$ from 4 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美東時間11月2日，多家華爾街大行更新了$默沙東 (MRK.US)$的評級，目標價介於120美元至125美元。
摩根士丹利分析師Terence Flynn維持持有評級，維持目標價123美元。
美銀證券分析師Charlie CY Yang維持買入評級，維持目標價120美元。
瑞士銀行分析師Colin Bristow維持買入評級，並將目標價從142美元下調至125美元。
Leerink Partners分析師Joseph Schwartz維持買入評級。
此外，綜合報道，$默沙東 (MRK.US)$近期主要分析師觀點如下：
隨着我們接近2024年，關於Gardasil和中國市場的持續不確定性在公司第三季度報告中得到了突出。 分析師已在第三季度收入超出預期並且公司基本保持其前景後修訂了估計。
默沙東第三季度的業績略高於預期，無論是營收還是每股收益。儘管如此，該公司的股票在調整其營收預測並降低每股收益指引後面臨一些壓力，現預計爲7.72至7.77美元，主要是由於與先前收購相關的費用。 展望未來，雖然2024年的營收預測基本相同，而每股收益預期略有增加，但由於預期的Gardasil銷售下降以及運營支出增加，2025年的估計已經有所調整。
默沙東對Gardasil的預期調整被視爲積極的發展，儘管引入新投資仍可能需要改變敘事。 Winrevair的潛力促使這種變化仍然存在不確定性。
以下爲今日4位分析師對$默沙東 (MRK.US)$的最新投資評級及目標價：
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
